Navigation Links
American Association for Cancer Research (AACR) Deploys Collexis' Reviewer Finder and Journal Dashboard Applications

Reviewer Finder to Speed up the Peer Review Process!

COLUMBIA, S.C., Feb. 18 /PRNewswire-FirstCall/ -- Collexis Holdings Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic search and knowledge discovery software, announced today that the American Association for Cancer Research (AACR) has licensed the Collexis' Reviewer Finder and Journal Dashboard applications for the 6 AACR cancer research journals.

(Logo: )

"The Collexis Review Finder application will certainly enhance and improve our peer review process as we continuously strive to target the most appropriate reviewers", stated Diane Scott-Lichter, Publisher of AACR. "The Journal Dashboard will provide us with key insights concerning the positioning of our journals in the area of cancer research."

"Having the AACR to sign up for our Reviewer Finder application is quite gratifying for us since AACR is the first society to adopt the Reviewer Finder for the publishing process - until today most of the Reviewer Finder customers were other funding organizations like the NHLBI at the NIH and the Wellcome Trust," said Christian Herzog, MD, Managing Director of the Collexis STM Business Unit. "As the AACR begins to use the Journal Dashboards as journal portfolio analysis tools, we are very confident that it will help them to sharpen the profile of their journals."

The Collexis Reviewer Finder helps publishing organizations in two very important ways: first it assists in reducing the time to identify the most qualified reviewers from hours to virtually minutes by automatically suggesting best matching reviewers for a manuscript, secondly it enhances security by identifying potential conflicts of reviewers based on co-authorship and institutional affiliation. The Collexis Reviewer Finder will be integrated into the publishing workflow solution that AACR is using.

The Collexis Journal Dashboard is providing the customer a complex view to analyze the portfolio of a journal, to compare it on a granular basis to others, to understand author patterns and emerging trends - providing insights for strategic decisions on positioning and further development.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with operations in Cincinnati, Ohio and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company's collaboration with the American Association for Cancer Research. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-K for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.

SOURCE Collexis Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American Institute for Medical and Biological Engineering Appoints Dr. Gualberto Ruano to College of Fellows
2. BioIQ Supports American Heart Month to Raise Awareness About Heart Disease, the #1 Killer of Women
3. New General Manager, Transition to New Raleigh Offices Highlight Datatrials Expansion of North American Operations
4. ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross
5. American Oriental Bioengineering to Participate in the 2009 UBS Greater China Conference
6. American Oriental Bioengineering Comments on Recent Property Purchase
7. Tips from the journals of the American Society for Microbiology
8. Elsevier Introduces The American Journal of Medicine Blog
9. The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database
10. Transgenomic Receives Accreditation From College of American Pathologists
11. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
Breaking Biology Technology:
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... Technology and Patent Infringement Risk Analysis" report to ... --> Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:11/20/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... recently interviewed on The RedChip Money Report ... on Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:11/19/2015)...  Based on its in-depth analysis of the biometric ... the 2015 Global Frost & Sullivan Award for Product ... this award to the company that has developed the ... the market it serves. The award recognizes the extent ... customer base demands, the overall impact it has in ...
Breaking Biology News(10 mins):